Role of baseline pol genotype in HIV-1 fitness evolution

被引:23
作者
Weber, J
Rangel, HR
Chakraborty, B
Marotta, ML
Valdez, H
Fransen, K
Florence, E
Connick, E
Smith, KY
Colebunders, RL
Landay, A
Kuritzkes, DR
Lederman, MM
Vanham, G
Quiñones-Mateu, ME
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Virol, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, Univ Hosp Cleveland, AIDS Res Ctr, Cleveland, OH 44106 USA
[3] Inst Trop Med, Immunol Lab, B-2000 Antwerp, Belgium
[4] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80202 USA
[5] Rush Univ, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
关键词
viral fitness; secondary mutations; protease;
D O I
10.1097/00126334-200308010-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Viral fitness can be modified upon development of antiretroviral drug resistance, usually by selection of compensatory mutations. In this study, we have used HIV-1 isolates from individuals receiving a protease inhibitor (PI)-based regimen to analyze the impact of basal genetic background on viral fitness evolution. Paired plasma samples and HIV-1 isolates were obtained from 10 PI-naive HIV-infected individuals enrolled in 2 different studies of combination antiretroviral therapy. Genomic regions from pol and env were sequenced. Viral fitness was measured using growth competition experiments followed by heteroduplex tracking analysis. Baseline genotypic analyses of pol showed that 9 of 10 viruses had a different degree of secondary mutations in the protease gene at codons associated with PI resistance (i.e., 10I, 36I, 63P, 71T, and 77I). After 48 weeks of PI-based therapy, a strong correlation was observed between protease genetic divergence and viral fitness difference (r = 0.78, P = 0.03), but not with reverse transcription or Env divergence, suggesting that genotypic changes in the protease gene were driving HIV-1 evolution in these patients. As expected, an inverse correlation was observed between the number of protease and reverse transcription primary mutations and viral fitness (r = -0.65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy.
引用
收藏
页码:448 / 460
页数:13
相关论文
共 59 条
[1]  
[Anonymous], HIV SEQUENCE COMPEND
[2]   Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].
Back, NKT ;
Nijhuis, M ;
Keulen, W ;
Boucher, CAB ;
Essink, BBO ;
vanKuilenburg, ABP ;
vanGennip, AH ;
Berkhout, B .
EMBO JOURNAL, 1996, 15 (15) :4040-4049
[3]   Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C [J].
Ball, SC ;
Abraha, A ;
Collins, KR ;
Marozsan, AJ ;
Baird, H ;
Quiñones-Mateu, ME ;
Penn-Nicholson, A ;
Murray, M ;
Richard, N ;
Lobritz, M ;
Zimmerman, PA ;
Kawamura, T ;
Blauvelt, A ;
Arts, EJ .
JOURNAL OF VIROLOGY, 2003, 77 (02) :1021-1038
[4]   Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults [J].
Barbour, JD ;
Wrin, T ;
Grant, RM ;
Martin, JN ;
Segal, MR ;
Petropoulos, CJ ;
Deeks, SG .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11104-11112
[5]   Natural variation in HIV-1 protease, gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1 [J].
Barrie, KA ;
Perez, E ;
Lamers, SL ;
Farmerie, WG ;
Dunn, BM ;
Sleasman, JW ;
Goodenow, MM .
VIROLOGY, 1996, 219 (02) :407-416
[6]   HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness [J].
Berkhout, B .
JOURNAL OF BIOMEDICAL SCIENCE, 1999, 6 (05) :298-305
[7]   Proposed alternatives for the use of anti-HIV drugs [J].
Berkhout, B .
DRUG RESISTANCE UPDATES, 1999, 2 (01) :69-70
[8]   CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo [J].
Berkowitz, RD ;
Alexander, S ;
Bare, C ;
Linquist-Stepps, V ;
Bogan, M ;
Moreno, ME ;
Gibson, L ;
Wieder, ED ;
Kosek, J ;
Stoddart, CA ;
McCune, JM .
JOURNAL OF VIROLOGY, 1998, 72 (12) :10108-10117
[9]   Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor [J].
Bossi, P ;
Mouroux, M ;
Yvon, A ;
Bricaire, F ;
Agut, H ;
Huraux, JM ;
Katlama, C ;
Calvez, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) :2910-2912
[10]  
Clavel F, 2000, Adv Pharmacol, V49, P41